Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

A reminder to all members that you agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


986 Pages (Click to Jump) V  « < 979 980 981 982 983 984 985 > »    
 
  
Reply to this topic

BLT, BENITEC BIOPHARMA LIMITED
jarm
post Posted: Aug 6 2004, 07:54 AM
  Quote Post


Posts: 552
Thanks: 7


I think I'll start accumulating some more at this price even if it means parking more money. Pretty soon reality will strike.

jarm

 
AgentCooper
post Posted: Aug 4 2004, 06:15 PM
  Quote Post


Posts: 1,475
Thanks: 34


I'd start worrying when they put out 3 announcements in 3 days - ala Chemeq - just to respond to media speculation.

The board have better things to do than worry about their tightly held stock - like getting on with the business of running business.

Regards,

Coop

 
jarm
post Posted: Aug 4 2004, 03:14 PM
  Quote Post


Posts: 552
Thanks: 7


This stock is bewildering me. They clearly hold the only IP that matters. Most stock is very tightly held and so minor movements have amplified effects. But the latest correction looks ridiculous since there is no bad news - just a lack of news from the company. You would think the tiny placements on offer would be taken up by the larger holders but perhaps they know what is going on and so don't bother with the process of supporting the share price. I'm holding for the medium term.

jarm

 
theadder
post Posted: Aug 2 2004, 09:47 AM
  Quote Post


Posts: 5,264
Thanks: 1136


New technique for 'switching off' genes could end fatal brain diseases

http://news.independent.co.uk/world/scienc...sp?story=546954


 
theadder
post Posted: Jul 30 2004, 10:17 AM
  Quote Post


Posts: 5,264
Thanks: 1136


The beak of the squid

http://www.eurekalert.org/pub_releases/200...l-tbo072804.php

Researchers reveal Argonaute2 as the catalytic engine of mammalian RNA interference

RNA interference (RNAi) has emerged as a fundamentally important biological phenomenon and as a versatile, powerful tool for biomedical research. In organisms from fungi and flies to plants and mammals, RNAi plays a multifaceted role in molecular biology by silencing genes through chromatin remodeling, interfering with protein synthesis, and--in its best-studied mode of action--quashing gene expression by cleaving messenger RNA. Experimental applications of RNAi have spurred the exploration of gene function in many basic research, drug discovery, and clinical settings. Until now, however, the identity of the molecular scissors that carry out RNAi-mediated messenger RNA cleavage has not been revealed.

Two studies published this week in Science have resolved this mystery by establishing that Argonaute2, a signature protein component of the RNA interference machinery, provides the cutting action that carries out RNAi-mediated messenger RNA cleavage. The studies were conducted at Cold Spring Harbor Laboratory by research groups led by Greg Hannon and Leemor Joshua-Tor.

Hannon's group focused on sorting out the functions of four mammalian Argonaute family members (Ago1, 2, 3, and 4). First, through a biochemical approach, Hannon and his colleagues found that only a single Argonaute family member, Ago2, supports the formation of mRNA cleavage-competent complexes in vitro.

To extend these biochemical findings to an in vivo setting, and to further explore the specialization of Argonaute family member function, Hannon's group disrupted the mouse Ago2 gene by targeted insertional mutagenesis. The researchers observed an embryonic lethal phenotype and striking developmental abnormalities in Ago2 homozygotes.

All Ago2 homozygous embryos displayed defects in neural tube structure, with half of the embryos showing complete failure of neural tube closure in the head region. The embryos also had enlarged hearts and pronounced swelling of the pericardial cavity, and were severely developmentally delayed compared to their wild-type and heterozygous littermates. In contrast to the critical developmental role of Ago2 revealed by these findings, work by researchers elsewhere has shown that other Argonaute family members are dispensable for development.

Hannon and his colleagues reasoned that if Ago2 is uniquely capable of assembling into mRNA cleavage-competent complexes in vivo, then mouse cells lacking Ago2 but containing other Ago proteins should be incapable of carrying out experimentally-triggered, siRNA-mediated mRNA cleavage.

The researchers observed just such a result with Ago2-deficient mouse cells, and showed further that a plasmid encoding human Ago2 (but not Ago1) could restore siRNA-mediated mRNA cleavage to Ago2-deficient mouse cells.

Hannon's study was consistent with the possibility that Argonaute2 provides the "Slicer" activity of RNAi-mediated mRNA cleavage. However, the possibility that a different protein provides Slicer activity could not be ruled out. Fortunately, Leemor Joshua-Tor's group, also at Cold Spring Harbor Laboratory, was simultaneously conducting x-ray crystallographic studies of an Argonaute protein (PfAgo) from the hyperthermophilic archaebacterium, Pyrococcus furiosus.

When Joshua-Tor and her colleagues determined the crystal structure of PfAgo, they found that the PIWI domain of PfAgo belongs to the RNase H family of enzymes, whose members have RNA cleavage activity. This finding immediately implicated Argonaute itself as the protein that provides the Slicer activity of RNAi in mammals and other organisms.

Hannon and Joshua-Tor had previously shown that another domain of Argonaute proteins, the PAZ domain, recognizes the 3' ends of siRNAs. That observation, combined with her group's discovery that the PIWI domain of PfAgo belongs to the RNase H family, enabled Joshua-Tor to propose a model for siRNA-targeted mRNA cleavage by Argonaute (see figure).

Collectively, the two new studies establish that Argonaute2 is the catalytic engine of mammalian RNAi and provide a specific, structural mechanism for siRNA-targeted mRNA cleavage by Argonaute.

Given the role of RNA interference in a wide variety of biological processes and the intense interest in RNAi as a tool for both basic and applied research, the studies by Hannon and Joshua-Tor are a significant advance toward a comprehensive understanding of one of the most intriguing and far-reaching biological phenomena to be uncovered in recent years.

*The term "Argonaute" refers to the squid-like appearance of the leaves of Arabidopsis mutants lacking AGO1 gene function (Bohmert et al., 1998). See also the Greek myth Jason and the Argonauts and the squid, Argonauta argo.

Cold Spring Harbor Laboratory is a private, non-profit basic research and educational institution. Under the leadership of Dr. Bruce Stillman, a member of the National Academy of Sciences and a Fellow of the Royal Society (London), more than 350 scientists at the Laboratory conduct groundbreaking research in cancer, neurobiology, plant molecular genetics, genomics, and bioinformatics.


###


 
theadder
post Posted: Jul 29 2004, 10:06 PM
  Quote Post


Posts: 5,264
Thanks: 1136


I do not hold BLT andyc, however, I agree it is looking a bit dicey.



 

Featured Stock Stories





andyc
post Posted: Jul 29 2004, 08:11 PM
  Quote Post


Posts: 188


well adder it looks like all the hard work at BLT is adding up to one giant red alarm bell... this one looks dicey as all hell right now... should be interesting nonetheless

 
theadder
post Posted: Jul 6 2004, 10:59 AM
  Quote Post


Posts: 5,264
Thanks: 1136


Biotech agrees research deal

http://finance.news.com.au/common/story_pa...5E14334,00.html

 
theadder
post Posted: Jul 5 2004, 06:03 PM
  Quote Post


Posts: 5,264
Thanks: 1136


Benitec grants Merck worldwide research license

http://www.egoli.com.au/egoli/egoliNewsVie...DD59D8E0431C%7D

 
theadder
post Posted: Jun 24 2004, 12:22 PM
  Quote Post


Posts: 5,264
Thanks: 1136


Delivering On RNA's Medical Promise

http://www.thejacksonchannel.com/technolog...531/detail.html

 
 


986 Pages (Click to Jump) V  « < 979 980 981 982 983 984 985 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING